Get the Stockscreener App
39.42
4.53%
-1.87
Tarsus Pharmaceuticals Inc stock is traded at $39.42, with a volume of 616.70K.
It is down -4.53% in the last 24 hours and down -9.79% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$41.29
Open:
$41
24h Volume:
616.70K
Relative Volume:
0.95
Market Cap:
$1.73B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-8.4957
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
-4.25%
1M Performance:
-9.79%
6M Performance:
-25.99%
1Y Performance:
+36.69%
1-Day Range:
$39.25
$41.16
1-Week Range:
$39.25
$42.12
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
39.42 | 1.73B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals Becomes Oversold (TARS) - Nasdaq
When (TARS) Moves Investors should Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Rhumbline Advisers Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth - Investing.com Australia
Tarsus Pharmaceuticals’ SWOT analysis: XDEMVY’s success propels stock growth By Investing.com - Investing.com India
Insider Sell: Aziz Mottiwala Sells 17,500 Shares of Tarsus Pharm - GuruFocus
Tarsus Pharmaceuticals CCO sells $765,800 in stock - Investing.com Australia
Tarsus Pharmaceuticals CCO sells $765,800 in stock By Investing.com - Investing.com South Africa
Certain Common stock of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2025. - marketscreener.com
Certain Stock Options of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2025. - marketscreener.com
Tarsus Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Focus By Investing.com - Investing.com Canada
Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - marketscreener.com
Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating - MSN
Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Where are the Opportunities in (TARS) - news.stocktradersdaily.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer - Defense World
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating - marketscreener.com
TARS: Oppenheimer Ups Tarsus Pharmaceuticals Price Target to $75 | TARS Stock News - GuruFocus
What is HC Wainwright’s Estimate for TARS Q2 Earnings? - Defense World
Nuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus to Participate in Upcoming Investor Conferences | TARS Stock News - GuruFocus
Tarsus Lines Up Triple Conference Appearances: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by HC Wainwright - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by HC Wainwright - Defense World
TARS: HC Wainwright & Co. Initiates Buy Rating with $72 Target | - GuruFocus
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
TARS: HC Wainwright & Co. Initiates Buy Rating with $72 Target | TARS Stock News - GuruFocus
TARS: H.C. Wainwright Initiates Coverage with a Buy Rating | TARS Stock News - GuruFocus
Tarsus Pharmaceuticals Advances Novel Treatments for Eye and Vector-Borne Diseases - utahdailynewswire.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $1.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DE - Defense World
Tarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with Xdemvy By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals Shows Rising Price Performance With Jump To 84 RS Rating - inkl
When the Price of (TARS) Talks, People Listen - news.stocktradersdaily.com
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Tarsus Pharmaceuticals Inc Enters Oversold Territory (TARS) - Nasdaq
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust Corp - Defense World
Transcript : Tarsus Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Tarsus Pharmaceuticals Breaks Below 200-Day Moving AverageNotable for TARS - Nasdaq
Tarsus Pharmaceuticals (TARS) Expected to Announce Earnings on Wednesday - Defense World
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off (NASDAQ:TARS) - Seeking Alpha
Tarsus to Participate in Upcoming Investor Conferences | TARS St - GuruFocus
Dimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals Reports First Quarter 2025 Sales Growth - VisionMonday.com
Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign - MSN
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs Group - Defense World
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):